DOCSLIB.ORG

Abita, X. Beaujouan

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Abita, X. Beaujouan AUTHOR INDEX FOR VOLUME 22 A Brothers, Virginia M. Three Adenylate Cyclase Phenotypes in S49 Lymphoma Cells Produced by Mutations of One Gene, 204 Abell, Creed W. See Denney, Patel, and Fritz, 500 Boyd, Michael R. See Wolf, Statham, McMenamin, Bend, and Phil- Abita, Jean-Pierre. See Gespach, Saal, and Cost, 547 pot, 738 Adams, Stephen M., and Kaminsky, Laurence S. Molecular Orbital Boyle, Michael R. See Hughes, Brown, Taylor, and Insel, 258 Studies of Epoxide Stability of Carcinogenic Polycyclic Aromatic Brothers, Virginia M. See Bourne, Beiderman, and Steinberg, 204 Hydrocarbon Diol Epoxides, 459 Brown, Oliver E. See Seduick, Hamrell, and Laszlo, 766 Adler, A. See Scheibel, 140 Brown, R. Dale. See Hughes, Boyle, Taylor, and Insel, 258 Affolter, Hubert, and Pletscher, Alfred. Storage ofBiogenic Amines Brune, K. See Mehler and Habicht, 525 in Intact Blood Platelets of Man: Dependence on a Proton Gra- Burt, Stanley. See Loeu’, Hashimoto, Williamson, and Anderson, dient, 94 667 Aguilar, Jos#{233} S., Salas, Pedro J. I., and De Robertis, Eduardo. Butcher, R. W. See Clark, Goka, Green, and Barber, 609 Cholinergic Muscannic Receptor in Synaptosomal Membranes: Heterogeneity of Binding Sites for L-[H]Quinuclidinyl Benzilate, C 304 Aktories, Klaus. See Grandt and Jakobs, 320 Cain, Bruce F. See Baguley, 486 Camus, J. See Chatelain, Robberecht, Waelbroeck, De Neef, and Albuquerque, Edson X. See Maleque, Souccar, and Cohen, 636 Christophe, 342 See Warnick, Jessup, Overman, Eldefrawi, Nimit, and Daly, 565 Caron, Marc G. See De Lean and Kilpatrick, 290 See Warnick, Maleque, Bakry, and Eldefrawi, 82 See Kilpatrick and De Lean, 298 Alvares, Alvito P. See Ueng, 221 Anderson, Wendie. See Loew, Hashimoto, Williamson, and Burt, Carter, Timothy H. See Rose and Leonard, 517 667 Catterall, William A. Andersson, Bo, Nordenskj#{246}ld, Magnus, Rahimtula, Anver, and See Costa, 196 Mold#{233}us, Peter. Prostaglandin Synthetase-Catalyzed Activation See Willow, 627 of Phenacetin Metabolites to Genotoxic Products, 479 Cech, Stella Y., and Maguire, Michael E. Magnesium Regulation of the Beta-Receptor-Adenylate Cyclase Complex. I. Effects of Man- Asao, Yukari. See Suketa, Yamada, and Hasegawa, 116 Aslaman, Dimitrina, and de Cheveign#{233}, Suzanne. Inelastic Elec- ganese on Receptor Binding and Cyclase Activation, 267 tron Tunneling Spectroscopic Study of Interaction of Acetylcho- Chatelain, P., Robberecht, P., Waelbroeck, M., De Neef, P., Ca- line and ,G-Methyl Acetylcholine with Alumina Surface, 678 mus, J., and Christophe, J. Thermodependence of Guanine Nucleotide-Activated Rat Cardiac Adenylate Cyclase Activity: Ef- fect of Cholera Toxin Pretreatment, 342 B Cheney, B. V., Lahti, R. A., Barsuhn, C., and Gay, D. D. An Bader, Hermann. See Gietzen and W#{252}thrich, 413 Analysis of Binding at the Opioid Receptor Based upon an Ago- Baguley, Bruce C., and Cain, Bruce F. Comparison of the in Vito nist/Antagonist Two-State Model, 349 and in Vitro Antileukemic Activity ofMonosubstituted Derivatives Cho, A. K. See Duncan, 235 of 4’-(9-Acridinylamino)methanesulfon-m-anisidide, 486 Cho, Arthur K., Maynard, Michael S., Matsumoto, Richard M., Bakry, Nabil Lindeke, Bj#{246}rn, Paulsen, Ulla, and Miwa, Gerald T. The Eldefrawi, Ainira T., Eldefrawi, Mohyee E., and Riker, Walter Opposing Effects of N-Hydroxyamphetamine and N-Hydroxy- F., Jr. Interactions of Quaternary Ammonium Drugs with Acetyl- phentermine on the H2O2 Generated by Hepatic Cytochrome P- cholinesterase and Acetyicholine Receptor of Torpedo Electric 450, 465 Organ, 63 Christophe, J. See Chatelain, Robberecht, Waelbroeck, De Neef, and See Warnick, Maleque, Eldefrawi, and Albuquerque, 82 Camus, 342 Barber, R. See Clark, Goka, Green, and Butcher, 609 Chwang, T. Ling. See Roberts, Franklin, Odom, and Peck, 760 Barsuhn, C. See Cheney, Lahti, and Gay, 349 Clark, R. B., Goka, T. J., Green, D. A., Barber, R., and Butcher, Batzri, Shmuel R. W. Differences in the Forskolin Activation of Adenylate Cy- Harmon, John W., and Thompson, William F. Interaction of clases in Wild-Type and Variant Lymphoma Cells, 609 Histamine with Gastric Mucosal Cells: Effect of Histamine Ago- Clark-Rosenberg, Reena. See Marangos, Patel, and Boulenger, 26 nists on Binding and Biological Response, 33 Clement-Cormier, Yvonne C. See Suen and Kwan, 595 Harmon, John W., Dyer, Jean, and Thompson, William F. Cohen, Jonathan B. See Maleque, Souccar, and Albuquerque, 636 Interaction of Histamine with Gastric Mucosal Cells: Effect of Coffins, Allan C. See Marks, 554 Histamine H2 Antagonists on Binding and Biological Response, 41 Conney, Allen H. See Vyas, Levin, Yagi, Thakker, Ryan, Thomas, Baxter, Diane. See Fischer, 231 and Jerina, 182 Beaujouan, J. C., Torrens, Y., Herbet, A., Daguet, M.-C., Glow- Conway, J. G., Kauffman, F. C., Ji, S., and Thurman, R. G. Rates inski, J., and Proehiantz, A. Specific Binding of an Immuno- of Sulfation and Glucuronidation of 7-Hydroxycoumarin in Pen- reactive and Biologically Active ‘251-Labeled Substance P Deriva- portal and Pericentral Regions of the Liver Lobule, 509 tive to Mouse Mesencephalic Cells in Primary Culture, 48 Cost, H#{233}l#{232}ne.See Gespach, Saal, and Abita, 547 Beiderman, Barry. See Bourne, Steinberg, and Brothers, 204 Costa, Maria R., and Catterall, William A. Characterization of Bend, John R. See Wolf, Statham, McMenamin, Boyd, and Philpot, Variant Neuroblastoma Clones with Missing or Altered Sodium 738 Channels, 196 Boulenger, Jean-Philippe. See Marangos, Patel, and Clark-Rosen- Covey, Douglas F. See Klunk and Ferrendelli, 431, 438, 444 berg, 26 Crippen, Gordon M. Distance Geometry Analysis of the Benzodiaze- Bourne, Henry R., Beiderman, Barry, Steinberg, Florence, and pine Binding Site, 11 803 804 AUTHOR IN1)EX Crooke, Stanley T. See Long, Willis, and Prestayko, 152 Line HL-60: Comparison with Human Peripheral Neutrophils, 547 Gewirtz, David A., Randolph, Joyce K., and Goldman, I. David. D Catecholamine-Induced Release of the Folic Acid Analogue, Meth- Daguet, M.-C. See Beaujouan, Torrens, Herbet, Glowinski, and Pro- otrexate, from Rat Hepatocytes in Suspension: An Alpha-Adre- chiantz, 48 nergic Phenomenon, 493 Dalmark, Mads, and Johansen, Peter. Molecular Association be- Gietzen, Klaus, W#{252}thrich, Andreas, and Bader, Hermann. Effects tween Doxorubicin (Adriamycin) and DNA-Derived Bases, Nu- of Microtubular Inhibitors on Plasma Membrane Calmodulin-De- cleosides, Nucleotides, Other Aromatic Compounds, and Proteins pendent Ca2-Transport ATPase, 413 in Aqueous Solution, 158 Glaumann, Hans. See Thomas, Ryan, von Bahr, and Levin, 190 Daly, John W. See Warnick, Jessup, Overman, Eldefrawi, Nimit, Glowinski, J. See Beaujouan, Torrens, Herbet, Daguet, and Pro- and Albuquerque, 565 chiantz, 48 Dannan, Ghazi A., and Guengerich, F. Peter. Immunochemical Goka, T. J. See Clark, Green, Barber, and Butcher, 609 Comparison and Quantitation of Microsomal Flavin-Containing Goldman I. David. See Gewirtz and Randolph, 493 Monooxygenases in Various Hog, Mouse, Rat, Rabbit, Dog, and Goren, H. J. See Hanif, Hollenberg, and Lederis, 381 Human Tissues, 787 Gorissen, H. See Ilien and Laduron, 243 Dax, Elizabeth M., and Partilla, John S. Adrenergic Ligand Lipo- Grandt, R#{252}diger, Aktories, Klaus, and Jakobs, Karl H. Guanine solubiity in Membranes: Direct Assessment in a Beta-Adrenergic Nucleotides and Monovalent Cations Increase Agonist Affinity of Binding System, 5 Prostaglandin E2 Receptors in Hamster Adipocytes, 320 de Cheveign#{233}, Suzanne. See Aslanian, 678 Green, D. A. See Clark, Goka, Barber, and Butcher, 609 De Lean, Andre Gruenwedel, Dieter W., and Diaham, Babou. Methylmercury(II)- Kilpatrick, Brian F., and Caron, Marc G. Dopamine Receptor of Induced Histone Perturbations in Nuclei Isolated from Calf Thy- the Porcine Anterior Pituitary Gland: Evidence for Two Affinity mus, 121 States Discriminated by Both Agonists and Antagonists, 290 Grunewald, Gary L. See Rafferty, 127 See Kilpatrick and Caron, 298 Guengerich, F. Peter. See Dannan, 787 See Vale, Lefkowitz, and Stadel, 619 Gylfe, Erik, and Heliman, Bo. Lack of Ca2 Ionophoretic Activity of De Neef, P. See Chatelain, Robberecht, Waelbroeck, Camus, and Hypoglycemic Sulfonylureas in Excitable Cells and Isolated Secre- Christophe, 342 tory Granules, 715 Denney, Richard M., Patel, Nutan T., Fritz, Richard R., and Abell, Creed W. A Monoclonal Antibody Elicited to Human H Platelet Monoamine Oxidase: Isolation and Specificity for Human Habicht, J. See Mehier and Brune, 525 Monoamine Oxidase B but Not A, 500 Hamrell, Michael. See Sedwick, Brown, and Laszlo, 766 De Robertis, Eduardo. See Aguilar and Salas, 304 Hamf, K., Goren, H. J., Hollenberg, M. D., and Lederis, K. Oxy- Diaham, Babou. See Gruenwedel, 121 tocin Action: Mechanisms for Insulin-Like Activity in Isolated Rat Duncan, J. D., and Cho, A. K. N-Oxidation of Phentermine to N- Adipocytes, 381 Hydroxyphentermine by a Reconstituted Cytochrome P-450 Oxi- Harden, T. Kendall. See Meeker, 310 dase System from Rabbit Liver, 235 Harmon, John W. Dyer, Jean. See Batzri, Harmon, and Thompson, 41 See Batzri and Thompson, 33 See Batzri, Dyer, and Thompson, 41 E Harrelson, Willard G., Jr., and Mason, Ronald P. Microsomal Eldefrawi, Amira T. Reduction of Gentian Violet: Evidence for Cytochrome P-450- Miller, E. Roxanne, Murphy, Deidre L., and Eldefrawi, Mohyee Catalyzed Free Radical Formation, 239 E. [‘H]Phencyclidine Interactions with the Nicotinic Acetylcholine Harris, R. Adron. See Stokes, 99 Receptor Channel and Its Inhibition by Psychotropic, Antipsy- Hasegawa, Jun. See Suketa, Yamada, and Asao, 116 chotic,
Load more

Recommended publications
  • Neurotransmitter Resource Guide
    NEUROTRANSMITTER RESOURCE GUIDE Science + Insight doctorsdata.com Doctor’s Data, Inc. Neurotransmitter RESOURCE GUIDE Table of Contents Sample Report Sample Report ........................................................................................................................................................................... 1 Analyte Considerations Phenylethylamine (B-phenylethylamine or PEA) ................................................................................................. 1 Tyrosine .......................................................................................................................................................................................... 3 Tyramine ........................................................................................................................................................................................4 Dopamine .....................................................................................................................................................................................6 3, 4-Dihydroxyphenylacetic Acid (DOPAC) ............................................................................................................... 7 3-Methoxytyramine (3-MT) ............................................................................................................................................... 9 Norepinephrine ........................................................................................................................................................................
    [Show full text]
  • Emerging Evidence for a Central Epinephrine-Innervated A1- Adrenergic System That Regulates Behavioral Activation and Is Impaired in Depression
    Neuropsychopharmacology (2003) 28, 1387–1399 & 2003 Nature Publishing Group All rights reserved 0893-133X/03 $25.00 www.neuropsychopharmacology.org Perspective Emerging Evidence for a Central Epinephrine-Innervated a1- Adrenergic System that Regulates Behavioral Activation and is Impaired in Depression ,1 1 1 1 1 Eric A Stone* , Yan Lin , Helen Rosengarten , H Kenneth Kramer and David Quartermain 1Departments of Psychiatry and Neurology, New York University School of Medicine, New York, NY, USA Currently, most basic and clinical research on depression is focused on either central serotonergic, noradrenergic, or dopaminergic neurotransmission as affected by various etiological and predisposing factors. Recent evidence suggests that there is another system that consists of a subset of brain a1B-adrenoceptors innervated primarily by brain epinephrine (EPI) that potentially modulates the above three monoamine systems in parallel and plays a critical role in depression. The present review covers the evidence for this system and includes findings that brain a -adrenoceptors are instrumental in behavioral activation, are located near the major monoamine cell groups 1 or target areas, receive EPI as their neurotransmitter, are impaired or inhibited in depressed patients or after stress in animal models, and a are restored by a number of antidepressants. This ‘EPI- 1 system’ may therefore represent a new target system for this disorder. Neuropsychopharmacology (2003) 28, 1387–1399, advance online publication, 18 June 2003; doi:10.1038/sj.npp.1300222 Keywords: a1-adrenoceptors; epinephrine; motor activity; depression; inactivity INTRODUCTION monoaminergic systems. This new system appears to be impaired during stress and depression and thus may Depressive illness is currently believed to result from represent a new target for this disorder.
    [Show full text]
  • Neurotransmitters-Drugs Andbrain Function.Pdf
    Neurotransmitters, Drugs and Brain Function. Edited by Roy Webster Copyright & 2001 John Wiley & Sons Ltd ISBN: Hardback 0-471-97819-1 Paperback 0-471-98586-4 Electronic 0-470-84657-7 Neurotransmitters, Drugs and Brain Function Neurotransmitters, Drugs and Brain Function. Edited by Roy Webster Copyright & 2001 John Wiley & Sons Ltd ISBN: Hardback 0-471-97819-1 Paperback 0-471-98586-4 Electronic 0-470-84657-7 Neurotransmitters, Drugs and Brain Function Edited by R. A. Webster Department of Pharmacology, University College London, UK JOHN WILEY & SONS, LTD Chichester Á New York Á Weinheim Á Brisbane Á Singapore Á Toronto Neurotransmitters, Drugs and Brain Function. Edited by Roy Webster Copyright & 2001 John Wiley & Sons Ltd ISBN: Hardback 0-471-97819-1 Paperback 0-471-98586-4 Electronic 0-470-84657-7 Copyright # 2001 by John Wiley & Sons Ltd. Bans Lane, Chichester, West Sussex PO19 1UD, UK National 01243 779777 International ++44) 1243 779777 e-mail +for orders and customer service enquiries): [email protected] Visit our Home Page on: http://www.wiley.co.uk or http://www.wiley.com All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, scanning or otherwise, except under the terms of the Copyright, Designs and Patents Act 1988 or under the terms of a licence issued by the Copyright Licensing Agency Ltd, 90 Tottenham Court Road, London W1P0LP,UK, without the permission in writing of the publisher. Other Wiley Editorial Oces John Wiley & Sons, Inc., 605 Third Avenue, New York, NY 10158-0012, USA WILEY-VCH Verlag GmbH, Pappelallee 3, D-69469 Weinheim, Germany John Wiley & Sons Australia, Ltd.
    [Show full text]
  • 2-Phenylethylamine and Methamphetamine Enhance the Spinal Monosynaptic Reflex by Releasing Noradrenaline from the Terminals of Descending Fibers
    Japan. J. Pharmacol. 55, 359-366 (1991) 359 2-Phenylethylamine and Methamphetamine Enhance the Spinal Monosynaptic Reflex by Releasing Noradrenaline from the Terminals of Descending Fibers Hideki Ono, Hiroyuki Ito and Hideomi Fukuda' Departmentof Toxicologyand Pharmacology,Faculty of Pharmaceutical Sciences, TheUniversity of Tokyo,Hongo 7-3-1, Bunkyo-ku, Tokyo 113, Japan 'Departmentof Pharmacology, Collegeof Pharmacy,Nihon University, 7-7-1Narashinodai, Funabashi, Chiba 274, Japan ReceivedJuly 28, 1990 AcceptedDecember 27, 1990 ABSTRACT Experiments were performed on spinalized rats transected at C1. In travenous administration of 2-phenylethylamine-HC1 (PEA-HC1) (0.3 and 1 mg/kg, i.v.) and methamphetamine-HC1 (MAP-HC1) (0.1 and 0.3 mg/kg, i.v.) increased the amplitude of the monosynaptic reflex (MSR). The increase of the MSR caused by PEA and MAP was antagonized by prazosin-HC1 and abolished by the pretreatment with reserpine (i.p.) and 6-hydroxydopamine (intracisternally, 14 days previously). A dopamine D, antagonist, SK&F 83566-HBr (0.01 mg/kg, i.v. ), and a D2 antagonist, YM-09151-2 (0.3 mg/kg, i.v.), did not antagonize the increasing effects produced by PEA and MAP. An inhibitor of type-B monoamine oxidase, (-)deprenyl-HC1 (1 mg/kg, i.v.), prolonged the effect of PEA but not that of MAP, suggesting that PEA alone, and not its metabolites, enhanced the MSR. These results suggest that PEA and MAP increase the amplitude of the MSR by releasing noradrenaline from the ter minals of descending noradrenergic fibers, and that PEA, an endogenous trace amine, has a mechanism of action similar to that of MAP.
    [Show full text]
  • Tyramine and Amyloid Beta 42: a Toxic Synergy
    biomedicines Article Tyramine and Amyloid Beta 42: A Toxic Synergy Sudip Dhakal and Ian Macreadie * School of Science, RMIT University, Bundoora, VIC 3083, Australia; [email protected] * Correspondence: [email protected]; Tel.: +61-3-9925-6627 Received: 5 May 2020; Accepted: 27 May 2020; Published: 30 May 2020 Abstract: Implicated in various diseases including Parkinson’s disease, Huntington’s disease, migraines, schizophrenia and increased blood pressure, tyramine plays a crucial role as a neurotransmitter in the synaptic cleft by reducing serotonergic and dopaminergic signaling through a trace amine-associated receptor (TAAR1). There appear to be no studies investigating a connection of tyramine to Alzheimer’s disease. This study aimed to examine whether tyramine could be involved in AD pathology by using Saccharomyces cerevisiae expressing Aβ42. S. cerevisiae cells producing native Aβ42 were treated with different concentrations of tyramine, and the production of reactive oxygen species (ROS) was evaluated using flow cytometric cell analysis. There was dose-dependent ROS generation in wild-type yeast cells with tyramine. In yeast producing Aβ42, ROS levels generated were significantly higher than in controls, suggesting a synergistic toxicity of Aβ42 and tyramine. The addition of exogenous reduced glutathione (GSH) was found to rescue the cells with increased ROS, indicating depletion of intracellular GSH due to tyramine and Aβ42. Additionally, tyramine inhibited the respiratory growth of yeast cells producing GFP-Aβ42, while there was no growth inhibition when cells were producing GFP. Tyramine was also demonstrated to cause increased mitochondrial DNA damage, resulting in the formation of petite mutants that lack respiratory function.
    [Show full text]
  • Selegiline) in Monkeys*
    Intravenous self-administration studies with /-deprenyl (selegiline) in monkeys* /-Deprenyl and its stereoisomer d-deprenyl did not maintain intravenous self-administration behavior in rhesus monkeys. In contrast, /-methamphetamine, the major metabolite of /-deprenyl, as well as the baseline drug, cocaine, maintained high rates of intravenous self-administration behavior. Treatment with /-deprenyl doses up to 1.0 mg/kg before self-administration sessions failed to alter self-administra- tion of either cocaine or /-methamphetamine. Thus /-deprenyl did not appear to have cocaine- or meth- amphetamine-like reinforcing properties in monkeys and was ineffective in altering established patterns of psychomotor-stimulant self-administration behavior. These results support clinical findings that de- spite long-term use of /-deprenyl for the treatment of Parkinson's disease by large numbers of patients, no instances of abuse have been documented. /-Deprenyl has recently been suggested as a potential med- ication for the treatment of various types of drug abuse, including cocaine abuse, but its failure to pro- duce selective effects in decreasing cocaine or methamphetamine self-administration behavior in the present experiments makes such an application seem unlikely. (CLIN PHARMACOL THER 1994;56:774-80.) Gail D. Winger, PhD,a Sevil Yasar, MD,b'd'e S. Steven Negus, PhD,a and Steven R. Goldberg, pIli/i d'e Ann Arbor, Mich., and Baltimore, Md. From the 'Department of Pharmacology, University of Michigan /-Deprenyl (selegiline) has been known for several
    [Show full text]
  • 212102Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 212102Orig1s000 OTHER REVIEW(S) Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research | Office of Surveillance and Epidemiology (OSE) Epidemiology: ARIA Sufficiency Date: June 29, 2020 Reviewer: Silvia Perez-Vilar, PharmD, PhD Division of Epidemiology I Team Leader: Kira Leishear, PhD, MS Division of Epidemiology I Division Director: CAPT Sukhminder K. Sandhu, PhD, MPH, MS Division of Epidemiology I Subject: ARIA Sufficiency Memo for Fenfluramine-associated Valvular Heart Disease and Pulmonary Arterial Hypertension Drug Name(s): FINTEPLA (Fenfluramine hydrochloride, ZX008) Application Type/Number: NDA 212102 Submission Number: 212102/01 Applicant/sponsor: Zogenix, Inc. OSE RCM #: 2020-953 The original ARIA memo was dated June 23, 2020. This version, dated June 29, 2020, was amended to include “Assess a known serious risk” as FDAAA purpose (per Section 505(o)(3)(B)) to make it consistent with the approved labeling. The PMR development template refers to the original memo, dated June 23, 2020. Page 1 of 13 Reference ID: 46331494640015 EXECUTIVE SUMMARY (place “X” in appropriate boxes) Memo type -Initial -Interim -Final X X Source of safety concern -Peri-approval X X -Post-approval Is ARIA sufficient to help characterize the safety concern? Safety outcome Valvular Pulmonary heart arterial disease hypertension (VHD) (PAH) -Yes -No X X If “No”, please identify the area(s) of concern. -Surveillance or Study Population X X -Exposure -Outcome(s) of Interest X X -Covariate(s) of Interest X X -Surveillance Design/Analytic Tools Page 2 of 13 Reference ID: 46331494640015 1.
    [Show full text]
  • Information to Users
    INFORMATION TO USERS This manuscript has been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely event that the author did not send UMI a complete manuscript and there are missing pages, these will be noted. Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginning at the upper left-hand corner and continuing from left to right in equal sections with small overlaps. Each original is also photographed in one exposure and is included in reduced form at the back of the book. Photographs included in the original manuscript have been reproduced xerographically in this copy. Higher quality 6" x 9" black and white photographic prints are available for any photographs or illustrations appearing in this copy for an additional charge. Contact UMI directly to order. University Microfilms International A Bell & Howell Information C om pany 300 North Z eeb Road. Ann Arbor. Ml 48106-1346 USA 313/761-4700 800 521-0600 Order Number 9120692 Part 1. Synthesis of fiuorinated catecholamine derivatives as potential adrenergic stimulants and thromboxane A 2 antagonists. Part 2.
    [Show full text]
  • The Enigma of Conditioned Taste Aversion Learning: Stimulus Properties of 2-Phenylethylamine Derivatives
    Physiol. Res. 51: S13-S19, 2002 The Enigma of Conditioned Taste Aversion Learning: Stimulus Properties of 2-phenylethylamine Derivatives A. J. GREENSHAW1, S. TURKISH2, B. A. DAVIS2 1Neurochemical Research Unit, Department of Psychiatry, University of Alberta and 2Neuropsychiatric Research Unit, University of Saskatchewan, Canada Summary The functional aversive stimulus properties of several IP doses of (±)-amphetamine (1.25-10 mg.kg-1), 2-phenylethylamine (PEA, 2.5-10 mg.kg-1, following inhibition of monoamine oxidase with pargyline 50 mg.kg-1) and phenylethanolamine (6.25-50 mg.kg-1) were measured with the conditioned taste aversion (CTA) paradigm. A two-bottle choice procedure was used, water vs. 0.1 % saccharin with one conditioning trial and three retention trials. (±)-Amphetamine and phenylethanolamine induced a significant conditioned taste aversion but PEA did not. (±)-Amphetamine and PEA increased spontaneous locomotor activity but phenylethanolamine had no effects on this measure. Measurement of whole brain levels of these drugs revealed that the peak brain elevation of PEA occurred at approximately 10 min whereas the peak elevations of (±)-amphetamine and phenylethanolamine occurred at approximately 20 min. The present failure of PEA to elicit conditioned taste aversion learning is consistent with previous reports for this compound. The differential functional aversive stimulus effects of these three compounds are surprising since they exhibit similar discriminative stimulus properties and both (±)-amphetamine and PEA are self- administered by laboratory animals. The present data suggest that time to maximal brain concentrations following peripheral injection may be a determinant of the aversive stimulus properties of PEA derivatives. Key words 2-phenylethylamine • (±)-amphetamine • Phenylethanolamine • Conditioned taste aversion • Locomotor activity • Drug levels Introduction (Greenshaw et al.
    [Show full text]
  • The Role of Norepinephrine in the Pharmacology of 3,4
    !"#$%&'#$&($)&*#+,-#+"*,-#$,-$."#$/"0*102&'&34$&($ 56789#."4'#-#:,&;41#."01+"#.01,-#$<9=9>6$?#[email protected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`,E#-E$ I0--$ D-.#*$ 2*#0.,J#2&11&-@X&*3a',2#-2#@aY48-28 -:aSX]a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
    [Show full text]
  • Principles-Of-Autonomic-Medicine-V
    Principles of Autonomic Medicine v. 2.1 DISCLAIMERS This work was produced as an Official Duty Activity while the author was an employee of the United States Government. The text and original figures in this book are in the public domain and may be distributed or copied freely. Use of appropriate byline or credit is requested. For reproduction of copyrighted material, permission by the copyright holder is required. The views and opinions expressed here are those of the author and do not necessarily state or reflect those of the United States Government or any of its components. References in this book to specific commercial products, processes, services by trade name, trademark, manufacturer, or otherwise do not necessarily constitute or imply their endorsement, recommendation, or favoring by the United States Government or its employees. The appearance of external hyperlinks is provided with the intent of meeting the mission of the National Institute of Neurological Disorders and Stroke. Such appearance does not constitute an endorsement by the United States Government or any of its employees of the linked web sites or of the information, products or services contained at those sites. Neither the United States Government nor any of its employees, including the author, exercise any editorial control over the information that may be found on these external sites. Permission was obtained from the following for reproduction of pictures in this book. Other reproduced pictures were from -- 1 -- Principles of Autonomic Medicine v. 2.1 Wikipedia Commons or had no copyright. Tootsie Roll Industries, LLC (Tootsie Roll Pop, p. 26) Dr. Paul Greengard (portrait photo, p.
    [Show full text]
  • Demonstration and Distribution of Phenylethanolamine in Brain And
    Proc. Nat. Acad. Sci. USA Vol. 70, No. 3, pp. 769-772, March 1973 Demonstration and Distribution of Phenylethanolamine in Brain and Other Tissues (enzyme assay/intraneural synthesis and storage/phenylethylamine/phenylalanine/rat) JUAN M. SAAVEDRA AND JULIUS AXELROD Laboratory of Clinical Science, National Institute of Mental Health, Bethesda, Maryland 20014 Contributed by Julius Axelrod, December 26, 1972 ABSTRACT A specific and sensitive assay for phenyl- of a mixture containing 10 ul of partially purified phenyl- ethanolamine in tissues is described. By this assay, phenyl- ethanolamine was detected in many peripheral tissues and ethanolamine N-methyltransferase, 5 Ml (0.54 nmol) of brains of rats. It is unequally distributed in rat brain, with [3H]methyl-S-adenosyl-l-methionine (specific activity, 4.54 the highest concentration present in hypothalamus and Ci/mmol) and 35 ul of 20 mM Tris * HCl buffer (pH 8.6). 1 ng midbrain. Concentrations of brain phenylethanolamine of phenylethanolamine was added to another aliquot as an were elevated after administration of phenylethylamine, internal standard. The incubation was stopped by addition of phenylalanine, p-chlorophenylalanine, and monoamine oxidase inhibitors and decreased after administration of 0.5 ml of 0.5 M borate buffer (pH 10) and the radioactive dopamine-fl-hydroxylase inhibitors. Denervation of sym- product was extracted with 6 ml of a mixture containing 95% pathetic nerves caused a moderate fall in phenylethanol- heptane and 5% isoamyl alcohol (v/v), by shaking for 15 sec. amine concentrations. These results indicate that phenyl- After the phases were separated by centrifugation, a 5-ml ethanolamine is synthesized intraneuronally from phenyl- alanine and phenylethylamine, but that only part of the aliquot of the organic phase was transferred to counting vials phenylethanolamine is stored in sympathetic nerves.
    [Show full text]